PWRM, PFE PennyToBuck.com Stock Report

July 9, 2010 - PRLog -- PWRM, Power 3 Medical Products Inc., PWRM.OB

PWRM is a leader in bio-medical research and the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets.

PWRM recently has unexpectedly discovered new and unprecedented findings regarding clinically important differences in the response of the NuroPro protein biomarkers in the blood of untreated Alzheimer’s disease patients compared to patients treated with the widely used anti-dementia drugs Aricept (Donepezil HCl, Pfizer – NYSE- PFE), Exelon (Rivastigmine, Novartis – NYSE- NVS), and Namenda (Memantine HCl, Forest Laboratories – NYSE- FRX). These results relate to the genetically distinct groups of Alzheimer’s disease patients, i.e., those individuals who possess the Alzheimer’s high-risk gene for Apolipoprotein E4 and those who do not possess the gene.

PWRM’s NuroPro was originally indicated for diagnostics to determine whether or not a patient had Alzheimer’s disease. With these results, PWRM’s NuroPro now extends into the pharmaceutical arena due to its ability to predict and monitor the response to drug treatment, including the underlying disease process and the insidious progression of irreversible neurological damage, even in the face of temporary improvements in cognition and other symptoms.

PWRM has filed for patent protection for these findings and will be publishing these seminal results in the near future in one of the world’s most prestigious peer-reviewed scientific journals.

** THE INTERNATIONAL CONGRESS OF ALZHEIMER’S DISEASE ACCEPTS FOUR SCIENTIFIC PRESENTATIONS BY PWRM **

Four abstracts were accepted for presentation to the annual meeting of the International Congress of Alzheimer’s Disease on July 12, 2010 in Honolulu, Hawaii. The presentations will cover results from protein biomarker discovery, drug response, test development, and ongoing clinical validation trials of the PWRM’s NuroPro AD biomarkers and blood test for Alzheimer’s disease.

The four studies to be presented involve a total of 154 Alzheimer’s disease patients and 91 Parkinson’s disease patients, as well as 210 age-matched normal control individuals and 173 disease control individuals.

- According to recent estimates, as many as 2.4 million to 4.5 million Americans have Alzheimer’s disease (AD). Unless the disease can be effectively treated or prevented, the number of people with AD will increase significantly if current population trends continue. That’s because the risk of AD increases with age, and the U.S. population is aging. The number of people age 65 and older is expected to grow from 39 million in 2008 to 72 million in 2030, and the number of people with AD doubles for every 5-year interval beyond age 65. (Source: CLICK HERE)

More about PWRM at www.power3medical.com



PFE, Pfizer Inc.

PFE, a biopharmaceutical company, engages in the discovery, development, manufacture, and marketing of prescription medicines for humans and animals worldwide.

** PFE reported a $100 million (U.S.) investment into the expansion of its Singapore Nutrition Plant, helping it continue to set the standard for the manufacture of high-quality, safe and environmentally sustainable nutritional products for infants and children.

This expansion, which brings the total investment in the plant to $372 million (U.S.), makes it one of the largest nutritional plants worldwide.

The plant is part of PFE Global Manufacturing’s Nutrition Operating Unit, a global Nutrition manufacturing network committed to setting the global quality standard for nutrition products used by infants and children. The network also operates manufacturing facilities in Ireland, China, Mexico and the Philippines.

More about PFE at www.pfizer.com

***********************************

For FREE Daily Stock Alerts & Updates Signup At: http://pennytobuck.com/signup
***********************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyToBuck.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyToBuck.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (read more ) Rule 17B requires disclosure of payment for investor relations.

# # #

Justin Handy
justin@crownequityholdings.com
Main: 702-448-1543
Fax: 702-479-7151
Toll Free: 1-877-854-6797
5440 W. Sahara Ave. Suite 205
Las Vegas,Nevada,89146